Pure Biologics' PBA-0405, a ROR1-targeting antibody engineered to induce tumor cell killing, has entered Phase 0 clinical trials, marking the first ROR1-targeting compound with its unique mechanism of action in human studies.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.